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ABSTRACT 
 Epigenetic modification is another mechanism involved in the cancer development 
besides classic mutations such as deletion. Aberrant promoter methylation and associated 
chromatin modification have been frequently reported in various tumors of different 
clinical stages. Hypermethylation has been frequently observed in tumor suppressor genes 
and causes reduced transcripts of these genes. Hypomethylation also has been reported to 
be involved in activation of oncogenes. Inactivation of the X chromosome and the 
imprinting of gamete DNA depend on the methylation patterns in the promoter region. 
Understanding methylation mechanisms could be helpful to diagnosis of early stage 
tumorgenesis or offer molecular markers for detecting cancers. 
 Changes in methylation patterns based on human vulva pathological tissue type of four 
genes have been studied in the current project. RASSF1A and DAPK-1 are tumor 
suppressor genes. BRCA2 is considered highly associated with breast and ovarian cancer. 
And H19 is a maternal imprinted gene. DAPK-1 and BRCA2 have been found to be 
significantly hypermethylated in Lichen Sclerosis (LS) and Squamous Cell Carcinoma 
(SCC). And RASSF1A has displayed an interesting methylation pattern in the post 
transcription region, where the frequency of methylation significantly decreased from 
normal tissue to LS tissue, but then dramatically increased to SCC. H19 failed to show any 
changes in the methylation pattern with methods tested. This was most likely due to 
interference of primer dimers by SYBR-green in the real-time PCR analyses. 
 Instead of using the same promoter sequence reported by previous papers, extended 
estimated promoter regions and partial transcription regions were obtained from Genome 
 viii
Browser and additional CpG island sites have been studied in current project. Methylation 
patterns have been detected that differ from the literature in these genes. These results may 
provide more information to find a more precise active promoter region and epigenetic 
involved sequences for future research.  
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CHAPTER ONE 
INTRODUCTION 
 
1.1. Epigenetic Modification and DNA Methylation 
The genetic information of an organism is written as a four-character code in DNA, 
and is highly regulated and organized. However, epigenetic modification may change the 
phenotype of a cell without altering its genotype, and that type of modification may also be 
heritable. DNA methylation associated with histone modification is the only known type of 
epigenetic modification essential in controlling gene expression under normal 
circumstances in human and mammalian cells (Biel et al. 2005).  
DNA methylation in eukaryotes always occurs at the 5 position of cytosine residues 
followed by a guanosine residue in a CpG dinucleotide configuration, but in some bacteria 
cells, methylation also takes place at adenine residues (Singal and Ginder 1999). Once 
cytosine residues have been methylated, accidental deamination leads to the conversion of 
methylcytosines to thymine residues which challenge DNA repair mechanisms (Antequera 
and Bird 1993). Therefore, the frequency of CpG normally is pretty low throughout the 
entire genome, representing only one base in around 1 per 50-100 (Feltus et al. 2003). 
Approximately 70% to 80% of the CpG sites contain methylated cytosines in most 
vertebrates, including
 
humans (Bird 1995).  
CpG islands are regions that are unusually rich in CpG sequences which range from 
0.5 to 5 kb in length and occur on average every 100 kb with distinctive properties (Bird 
1992). These regions are mostly unmethylated, GC rich (60% to 70%), and have a ratio of 
CpG to GpC of at least 0.6 (Cross and Bird 1995). There are at least 29,000 such regions in 
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the human genome, many of which reside in the 5’end of genes (Feltus et al. 2003). 
Chromatin contained in CpG islands is generally heavily acetylated, lacks histone H1, 
includes a nucleosome-free region which may allow or be a consequence of, the interaction 
of transcription factors with gene promoters (Singal and Ginder 1999). Each gene builds its 
own methylation pattern through specific methyltranferases and maintains its pattern 
through mitosis. Aberrant methylation in the promoter regions of genes interferes with gene 
expression and may be involved in many human diseases. Figure1.1 shows the biochemical 
pathways for cytosine methylation, demethylation, mutagenesis of cytosine and 5-mC and 
the enzymes involved in those pathways. 
1.2. Functions of DNA Methylation 
1.2.1 Roles in Gene Expression 
1.2.1.1 Regulating Gene Expression 
Experiments have shown that DNA methylation in the promoter region is related to gene 
transcriptional repression and gene silencing. Although the real mechanism of how DNA 
methylation results in gene silencing is still unclear, three possibilities have been proposed. 
First, DNA methylation might directly interfere with
 
the binding of specific transcription 
factors to their recognition
 
sites in their respective promoters (Tate and Bird 1993).Second, 
it might cause the direct binding of specific transcriptional repressors
 
to methylated 
DNA(Rountree and Selker 1997). Lastly, it also might alter chromatin structure such as 
deacetylation of the core histones H3 and H4 (Singal et al. 1997). However, whether 
methylation is a primary control
 
mechanism or a secondary effect, gene silencing is still an 
important issue in human disease that needs to be addressed (Singal and Ginder 1999). 
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Figure1.1. Schematic representation of the biochemical pathways for cytosine methylation, 
demethylation, and mutagenesis of cytosine and 5-mC (modified figure from Singal and 
Ginder 1999). 
 
 
1.2.1.2 Involved in Cancer (Carcinogenesis) 
The patterns of DNA methylation are gene-specific, and tissue specific, so that a 
unique set of proteins are only expressed to perform functions specific for a certain type of 
cell. Therefore, DNA methylation patterns play a critical role in silencing specific genes
 
during development and cell differentiation (Singal and Ginder 1999). Numerous studies 
have shown that aberrant methylation patterns in the promoter regions are among the 
earliest and most common events in tumorigenesis. Activation of proto-oncogenes through 
hypomethylation,
 
transcriptional inactivation of tumor-suppressor genes through
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hypermethylation, and defects in chromosomal segregation due to
 
failure of de novo 
methylation may all contribute to neoplasia (Singal and Ginder 1999).  
Hypomethylation may be an important etiological component of cancer development. 
Experiments have shown that hypomethylation is involved in gene activation, repetitive 
elements de-repression, and chromosomal instability (Scarano et al. 2005). Global 
hypomethylaiton was the first epigenetic abnormality to be identified in cancer cells (Scarano 
et al. 2005). Experiments have also shown that promoter hypomethylation is associated with 
cancer by activation of expression of normally silenced genes such as oncogenes (Chen et al. 
1998). H-ras which regulates signal transduction is an important example of a 
hypomethylated oncogene (Feinberg and Tycko 2004).  
Hypermethylation is opposite to hypomethylation which refers to the increasing level of 
methylation. Since aberrant promoter hypermethylation could inactivate normally expressed 
genes, it contributes to silencing of tumor suppressor genes (Singal and Ginder 1999). 
Aberrant promoter hypermethylation has been found to be involved in almost all the 
important steps of carcinogenesis: cell-cycle regulation, DNA repair, drug resistance and 
detoxification, apoptosis, cell differentiation, angiogenesis and metastasis (Scarano et al. 
2005). A lot of tumor suppressor genes such as retinoblastoma gene (Rb), p16, P53, VHL, 
MLH1, and BRCA1 have been detected to be involved in transcriptional inactivation in 
cancer cells (Lim et al. 2003). The retinoblastoma gene (Rb) was the first classic 
tumor-suppressor gene to be detected with promoter hypermethylation (Lim et al. 2003). P16 
is known as one of the most important cell cycle regulatory proteins, and hypermethylation 
mediated inactivation of the
 
p16 gene has been demonstrated in brain, breast, colon, head and
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neck, and non-small-cell lung cancer and in high grade non-Hodgkin's
 
lymphoma (Baylin et 
al. 1998). Mutations in the
 
p53 tumor-suppressor gene occur in more than 50% of human 
solid
 
tumors (Greenblatt et al. 1994).  
1.2.2 Genomic Imprinting and X Chromosome Inactivation 
Genomic imprinting is a particularly important mechanism in mammals. Genomic 
imprinting refers to the expression of a gene in the developing embryo being dependent on 
the allele’s parental origin (Feinberg et al. 2002). Over 70 imprinted genes have been 
identified in mammals so far (Murphy and Randy 2003). DNA methylation has been found 
to be the most consistent difference between the alleles of an imprinted gene, accompanied 
by differences in chromatin conformation, histone modification, replication timing and 
recombination rate (Paulsen and Ferguson-Smith 2001). 
The reason for imprinting has not been conclusively identified todate, but the most 
prominent assumption is that this process is necessary for development and may somehow 
regulate growth in the embryo and behavior after birth (Paoloni-Giacobino and Chaillet 
2004). Another theory based on evolution proposes that imprinting reflects the competing 
interests of the maternal and paternal genomes in the developing embryo (Murphy and 
Randy 2003).  
In mammals, the random inactivation of one X chromosome also occurs by 
methylation and histone H4 deacetylation (Scarano et al. 2005). This pattern is initiated at 
blastocyst stage, around the time of implantation, and is maintained in all somatic cells 
throughout (Maxfield Boumil and Lee 2001). 
Loss of imprinting (LOI) is the disruption of imprinted epigenetic marks through gain 
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or loss of DNA methylation (Kaplan et al. 2003). Studies of LOI have shown it plays roles 
in cancer. LOI of IGF2 is the most common event across the widest range of tumor types 
including colon, liver, lung, and ovarian cancer, as well as Wilms’ tumor which is the 
embryonic kidney cancer where LOI was first discovered (Robertson 2005). Research has 
shown that imprinting plays a role in the development of disease. (Peterson and Sapienza 
1993) reviewed various disease syndromes caused by aberrant imprinting. The best 
characterized syndromes related to growth and behavioral defects are 
Beckwith–Wiedemann syndrome (BWS) on chromosome 11p and the 
Prader–Willi/Angelman syndrome (AS) on chromosome 15q. 
1.2.3. Roles in Evolution  
From prokaryote, to nonvertebrate eukaryotes and vertebrates, the size of the genome
 
has increased from a few thousand genes to
 
 greater than 30,000genes (Bird 1995). And 
the frequency of methylation of cytosine occurs much less in invertebrates to none in some 
species such as Drosophila (Singal and Ginder 1999). (Bird 1995) proposed that since the 
greater the number of tissue specific genes, the greater the efficiency of gene transcription 
required. Therefore, DNA methylation in vertebrates reduces the transcriptional noise 
through a global repression, and thereby
 
allows vertebrates to accumulate and selectively 
use the extra
 
genes that are crucial to their
 
development. DNA methylation is also 
considered as a type of cell self-defense system during evolution(Yoder et al. 1997). It can 
inactivate the promoter of most viruses and transposons, including retroviruses and Alu 
elements (Singal and Ginder 1999). In addition, specific endonucleases may recognize 
foreign DNAs since they have a different methylation pattern from host cells, and thus 
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destroy those exogenous DNA fragments (Yoder et al. 1997).   
1.3. Enzymes Involved in DNA Methylation 
The methyl group is transferred from S-adenosylmethionines (SAM) to the 5 carbon of 
cytosine ring through the action of DNA methyltransferses (DNMT), and SAM is converted 
to S-adenosyl-homocysteine (SAH) (Campbell and Szyf 2003). Figure 1.2 illustrates the 
mechanism of DNMT methylation via the SAM pathway (Strathdee and Brown 2002). DNA 
methyltransferases establish the methylation pattern through de novo methylation, and then 
maintain the specific pattern after semi-conservative DNA synthesis (Bestor 2000).  
 
Figure1.2. Mechanism of DNA methylation.5-Methylcytosine is produced by the action of 
the DNA methyltransferases (DNMT 1, 3a or 3b), which catalyze the transfer of a methyl 
group (CH3) from S-adenosylmethionine (SAM) to the carbon-5 position of cytosine. 
(modified from Strathdee and Brown 2002) . 
 
 
Three methyltransferases genes (DNMT1, DNMT3A, DNMT3B) and one candidate gene, 
DNMT2, have been identified. DNMT1, the first one identified and cloned, is highly 
conservative in eukaryotes, and responsible for maintaining DNA methylation patterns 
during DNA replication (Figure1.3) (Robert et al. 2003). It plays essential roles in 
X-inactivation, genomic imprinting and genome stabilization (Bestor 2000). DNMT3A and 
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DNMT3B are essential for de novo methylation and play important roles in normal 
embryonic development and disease such as ICF syndrome (Okano et al. 1999). DNMT2 has 
been identified in human and mouse which appears to lack the large N-terminal regulatory 
domain common to other eukaryotic methyltransferases (Yoder and Bestor 1998). Recent 
studies also have suggested aberrations
 
in DNA methyltransferase activity in tumor cells 
(Singal and Ginder 1999). 
Besides methyltransferases, another enzyme called demethylase has been proposed to 
direct the removal of the methyl
 
group from methylated CpG (Bestor, 2000). However, no 
demethylase enzyme or gene has been identified or isolated to date. 
 
 
 
Figure1.3: Inheritance of the DNA methylation pattern.The original methylation pattern is 
maintained through mitosis The maintenance methylase can methylate only the CG 
sequence paired with methylated CG.  The CG sequence not paired with methylated CG 
will not be methylated.  
(modified from www.web-books.com/MiBio/Free/ch7F2.htm) 
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1.4. Causes of Aberrant Methylation 
Disruption of normal DNA methylation patterns may occur as a consequence of 
exposure to toxic agents, disease processes, and/or nutritional deficiencies.  
Along with dietary factors, aging, chronic inflammation, viral infection, and exposure 
to epimutagens all may cause aberrant methylation (Ushijima and Okochi-Takada 2005). 
Among those, aging, chronic inflammation, viral infections, chemicals including nickel, 
butyrate, and arsenic can induce aberrant methylation. Folate deficiency, choline deficiency, 
and 5-aza-2’-deoxycytidine (5-zaz-dC) and its derivatives cause hypomethylation(Ushijima 
and Okochi-Takada 2005). 
Folate is a water soluble B vitamin and an important mediator in methyl group 
metabolism (Kim 1999). 5-Methyl-terahydrofolate is a precursor of SAM and is the 
primary methyl donor for most biological methylations (Sohn et al. 2003). A lack of folate 
could increase the risk of cancer (Trasler et al. 2003).  
1.5. Studies of Epigenetic Instability 
Since DNA methylation is involved in gene regulation, evolution, cancer development, 
genetic imprinting and X chromosome inactivation, and it is also unlike mutational 
inactivation. Methylation is reversible and demethylating agents and inhibitors of histone 
deacetylases could be used in clinical trails, knowing the mechanism of DNA methylation 
may therefore have important
 
clinical implications for the prevention and treatment of 
human diseases. Studies of DNA methylation have been performed for several decades, but 
the understanding of the whole puzzle is still very limited. The relationship between gene 
regulation, DNA methylation, histone deacetylation, histone acetylation, methyltransferases,
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demethylases, methyl cytosine binding proteins,
 
and the transcriptional activity of
 
genes are 
the necessary information to understanding epigenetic mechanisms and need to be fully 
studied.  
Epigenetic instability is measured by the detection of abnormal methylation of DNA 
sequences, primarily promoter regions of oncogenes, tumor supressor and imprinting genes. 
These procedures are based on PCR and MS-PCR (methylation specific-PCR) techniques 
and gel electrophoresis, and occassionally include restriction endonuclease digestion. DNA 
is treated with bisulfite to convert non-methylated cytidine residues to uridine (and then 
thymidine upon PCR amplification), while the methylated cytidine (5-methyl-cytidine) 
residues remain unchanged(Frommer et al. 1992). These procedures are well published and 
the techniques are currently in use in our laboratory.  
The present project will enable the study of the methylation status of genes from 
normal skin to a preneoplastic disease (lichen sclerosus) state to squamous cell carcinoma. 
I begun this work with PCR primer sets specific for methylated and unmethylated 
sequences that are reported in the literature for each gene. New primers were designed 
where necessary for the development of a more sensitive DNA methylation assay. 
Methylation Specific PCR is used to distinguish methylated from unmethylated DNA in 
this assay.  
1.6. Gene Selection 
Four genes were chosen for methylation analyses: DAPK- 1, RASSF1A, BRCA2 and 
H19. Numerous publications in the literature have demonstrated the common occurrence of 
hypermethylation of tumor suppressor genes in diagnosed cancers(Looijenga et al. 1997; 
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Dammann et al. 2000; Reddy et al. 2003; Robertson 2005). But no one has verified the 
status of those methylation changes early in the tumorigenic process of skin squamous cell 
carcinoma (SCC). RASSF1A and DAPK-1 have been reported to be hypermethylated in 
cancers, and are studied here to for their methylation status in skin cancers. Although H19 
is an imprinted gene, no one has reported it being hypomethylated in human cancer. 
BRCA2 has been reported to be involved in breast cancer, but the methylation status in skin 
cancers has not been reported yet.  
1.6.1 RASSF1A 
The RASSF1 gene locus spans about 11,151 bp of the human genome which includes 
eight exons, and differential promoter usage and alternative splicing generated seven 
isomers (A-G) (Agathanggelou et al. 2005). RASSF1A is located at the 3p21.3 locus and is 
considered to be a tumor suppressor gene which is frequently inactivated by epigenetic 
events rather than classic mutation/deletion events (Vos et al. 2004; Agathanggelou et al. 
2005). RASSF1A has been reported to be involved in apoptotic signaling, microtubule 
stabilization and mitotic progression (Dammann et al. 2005). However, the precise 
mechanisim of how RASSF1A protein functions in cell cycle regulation and tumor 
suppression remains unknown (Vos et al. 2004). 
Abberant hypermethylation of the RASSF1A  promoter region has been reported in a 
number of human primary tumors (>90 PubMed entries) and was observed initially in lung 
cancer (Dammann et al. 2000). Those tumors include epithelial origin tumors such as breast, 
cervix, liver, small cell lung carcinomas, nasopharyngeal carcinomas, renal cell carcinomas, 
prostate carcinomas, and non-epithelial origin tumors such as neuroblastomas (Spugnardi et 
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al. 2003). Hypermethylation of  the promoter region also has been detected in body fluids 
including blood, urine, nipple aspirates, sputum and bronchial alveolar lavages (Dammann 
et al. 2005). Therefore, detection of aberrant RASSF1A methylation may serve as an early 
diagnostic and prognostic marker for cancer.  
1.6.2 DAPK1 
Death-associated protein kinase 1 (DAPK1) is located in 9q34.1, and it is a 160-kDa 
calcium/calmodulin-dependent serine-threonine kinase. It is required for γ 
interferon-induced apoptosis and is considered to be a tumor suppressor gene (Lehmann et 
al. 2002). Previous studies have shown that treatment with 5-aza-2’deoxycytidine (a 
demethylation reagent) on non-expressing cell lines resulted in expression of DAPK-1 gene 
product, which suggested epigenetic invovlment (Katzenellenbogen et al. 1999). Numerous 
studies have shown silencing of DAPK due to promoter hypermethylation plays role in lung, 
esophageal, head and neck, prostate, bladder, gastric, and B-cell malignancies including 
B-cell lymphoma, multiple myeloma, and Burkitt’s lymphoma (Reddy et al. 2003). 
However, the timing of DAP-kinase inactivation by methylation during tumor development 
has not been established (Pulling et al. 2004).  
1.6.3 H19 
H19 is the first human gene recognized to be paternally imprinted where the paternal 
allele is inactivated through methylation (Brannan et al. 1990). It is located in chromosome 
11p15.2 in both mice and humans within a cluster of at least five imprinted genes, 
including IGF2 (Zemel et al. 1992; Morison et al. 2001). IGF2 and H19 are reciprocally 
imprinted and coordinately regulated by an intergenic imprinting center and a common 
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enhancer region (Kopf et al. 1998). IGF2 is an autocrine growth factor with an important 
role in many types of cancer, and H19 is a non-coding RNA of unknown function with 
growth suppressive properties, possibly functions as a tumor suppressor or oncofetal gene 
(Hao et al. 1993). Loss of imprinting (LOI) of H19 has been observed in human 
malignancies, including lung cancer (Kaplan et al. 2003). But it is also interesting that 
up-regulation of H19 without LOI was found in the airway epithelium of cigarette smokers 
(Kaplan et al. 2003). H19 is normally expressed during embryogenesis at high levels in 
many organs (Lustig et al. 1994). In humans, there is biallelic expression of H19 in the 
placenta at <10 weeks of gestation, but expression becomes monoallelic after 18-20 weeks 
(Zhang and Tycko 1992). In adults, H19 expression remains monoallelic, with expression 
primarily in skeletal muscle, thymus, heart, and lung (Looijenga et al. 1997). 
1.6.4 BRCA2 
BRCA1 and BRCA2 are two breast cancer susceptibility genes which have become 
integrated into the practice of clinical oncology (Narod and Foulkes 2004). BRCA1 is 
located at chromosome17q21, and BRCA2 is located at 13q12.3 (King MC 2001).  
BRCA1 plays roles in DNA repair, cell-cycle-checkpoint control, ptotein 
ubiquitylation and chromatin remodeling (Scully and Livingston 2000). However, BRCA2 
is only known to be involved in homologous recombination (Narod and Foulkes 2004). 
Hypermethylation of the BRCA1 promoter has previously been shown to cause reduced 
mRNA expression in both breast and ovarian cancer (Chan et al. 2002), but 
hypomethylation of the BRCA2 promoter region has been demonstrated in sporadic 
ovarian cancer (Chan et al. 2002). No paper has report hypermethylaiton of BRCA2 
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associated with reduced mRNA expression yet. Studies have found high frequencies of 
hypermethylation of BRCA1 and hypomethylation of BRCA2 occurred within the same 
specimens, so both of them may be important in the development of sporadic ovarian 
cancer (Chan et al. 2002). 
1.7. Pathological Types of Skin 
1.7.1 Lichen Sclerosus (LS) 
Lichen sclerosus (LS) is a chronic inflammatory dermatosis that is not contagious (Boms 
et al. 2004). Any skin may be involved but the most common site is the genitalia which 
represents around 85% to 98% of cases (Oyama et al. 2004). It has been reported that LS 
affects women 6 to 10 times more often than men (Arican et al. 2004). The affected skin is 
often itchy, usually white and sometimes with fine, crinkling texture (Arican et al. 2004). As 
the condition progresses, bruising and pain may occur (Arican et al. 2004). Although it is still 
not fully understood what causes lichen sclerosus (LS), it is generally thought that it is not 
caused by a virus, bacteria, or fungus but something else entirely. Patients who with untreated 
disease have an increased risk of a skin cancer of the involved areas, which amounts to 
around 5% of cases that progress to malignancy most frequently squamous cell carcinoma 
(Oyama et al. 2004). 
 1.7.2. Squamous Cell Carcinoma 
American Academy Dermatology (http://www.aad.org/) states that   squamous cell 
carcinoma (SCC), the second most common skin cancer after basal cell carcinoma, afflicts 
more than 250,000 Americans each year. It arises from the epidermis and resembles the 
squamous cells that comprise most of the upper layers of skin and may occur on all areas of 
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the body including the mucous membranes. SCC is mainly caused by UV light 
(http://www.skincancer.org/). Squamous cell carcinomas usually appear as crusted or scaly 
patches on the skin with a red, inflamed base, a growing tumor, or a non-healing ulcer 
(http://www.aad.org/). SCCs are usually locally destructive but if it left untreated, it eventually 
penetrates and invades the underlying tissues. In a small percentage of cases, SCCs spread 
(metastasize) to distant tissues and organs. When this happens, SCCs can be fatal 
(http://www.skincancer.org/). 
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CHAPTER TWO 
MATERIAL AND METHODS 
 
2.1 Sample Collection and Labeling 
Human vulva tissues from over 100 patients were provided by Dr. Andrew Carlson of 
Albany Medical College. Squamous carcinoma with adjacent lichen sclerosis and 
surrounding normal tissues were obtained from each patient following therapy prescribed 
radical vulvectomy; all of the surgically resected tissues were  histologically analyzed. 
Normal tissues from patients with no apparent vulva ailment were also collected and used 
as uninvolved sample controls. Specimens were collected under approved IRB protocols 
with informed consent from all surgical patients. Tissues were separately labeled and 
packed based on the histological types and patients. Then tissues specimens were shipped 
on dry ice and stored at -80 °C until further analysis. 
Letter “CW” were assigned to samples from individuals with histological types associated 
with cancer (SCC), lichen sclerosis (LS), and normal adjacent tissues. The number after 
“CW” represents the patient’s number. A different number refers to different individual. The 
sub-grouping (last number in the sequence) is an identifier used to discriminate multiple 
tissues taken from one patient. 
2.2 Genomic DNA Preparation 
Two different DNA extraction procedures were used to purify DNA from samples. The 
first one was a standard phenol and choloroform extraction protocol which is a universal 
technique and the details are listed in appendix A. Equal volume phenol and choloroform are 
used to remove proteins (e.g., Dnases and other enzymes) and followed by precipitation of 
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the DNA. Details of this protocol have been listed in appendix A. The second procedure 
utilized the QIAamp DNA Mini Kit (Qiagen Inc., Chatsworth, CA) which makes the 
extraction of DNA more efficient. In both protocols, DNA are precipitated by cold ethanol 
and re-suspended in 1x TE buffer (Appendix B). The isolated DNAs were quantified through 
a Beckman DU-64 Spectrophotometer.  
2.3 Bisulfite Treatment of Isolated DNA 
The purpose of this published procedure (Frommer et al. 1992) is to convert 
unmethylated Cytosine to Uracil, without changing the methylated cytosine residues (Figure 
2.1). After the modification, the two daughter strands of modified DNA will no longer be 
complementary to each other. For the present study, approximately 1-2µg of DNA was 
denatured in NaOH and modified by sodium bisulfite treatment following the protocol of 
(Herman et al. 1996). Then the modified DNA samples were purified by using the Wizard 
DNA purification kit (Promega), treated again by NaOH and precipitated by cold ethanol. 
Dry DNA pellets were stored at -80°C and re-suspended in 20µl of 0.1X TE. Details of this 
protocol have been listed in appendix C. 
2.4 Methylation Specific PCR  
2.4.1 Gene Specific Sequences  
Gene promoter sequences were originally obtained from published papers identified on 
PubMed, but after comparison by BLAT (http://www.genome.ucsc.edu/cgi-bin/hgBlat), the 
published sequences were found to be incomplete with modified mRNA sequences. 
Therefore, Genome Browser( http://www.genome.ucsc.edu) was used to search the complete 
gene sequences. Promoter sequences were estimated to be 1000bp upstream from the first 
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exon of each gene.  
 
 
 
Figure 2.1 The Mechanism of Bisulfite Treatment. 
(modified from www.methods-online.net) 
 
 
2.4.2 Methylation-Specific PCR Primer Design 
Methprimer (http://www.ucsf.edu/urogene/methprimer/) was used to find out the regions 
of CpG islands within estimated promoter sequences and partial cDNA sequence. 
MethPrimer, which is based on Primer3, is a program designed for the production of MSP 
primers (Li and Dahiya 2002).  
Primers for RASSF1A and DAPK were originally chosen based on published papers 
(Herman et al. 1996; Lehmann et al. 2002), but PCR amplifications lacked the required 
specificity. Therefore, Methprimer was used to design primer sets for both methylated and 
unmethylated sequences for all the four genes. Primers were designed within each CpG island 
and incorporated at least 3 non-CpG cytosines in the original sequence to assure that 
unmodified DNA will not serve as a template for the primers. The last three bases at the 
3’-end of primers contained at least one CpG sequences. This provides optimal specificity 
and minimizes false positives due to mispriming. Primers in the M (methylated) pair and U 
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(unmethylated) pair also contained the same CpG sites within their sequence. Both M and U 
sets of primers should preferably have similar Tm values, thus allowing the two PCR 
reactions for each sample to be carried out simultaneously in the same PCR reaction under 
the same annealing conditions.  
2.4.3 Methylation Specific PCR Amplification 
After bisulfite conversion, the modified DNA was ready to be used as a template for U 
and M PCR analyses. Methylation PCR (M primer set) was designed to be specific for DNA 
originally methylated for the gene of interest, and unmethylation PCR (U primer set) was 
designed to be specific for DNA originally unmethylated. PCR products were separated on 
2% agarose gels and the bands were visualized by staining with ethidium bromide using UV 
fluorescence. The presence of a band indicates the presence of unmethylated, and/or 
methylated alleles, in the original sample. MSP was very sensitive, and permitted the analysis 
of small and heterogeneous samples, including paraffin-embedded material. 
Twenty µl PCR amplifications were performed under the following conditions: 2µl of 
modified DNA (50-100ng), 1µl of primers (final concentration is 0.125µM), 10µl of 
TAKARA Real Time Pre-Mix (Takara Mirus Bio) and 7µl of water. All reactions were 
subjected to the an initial denaturation step at 95ºC for 30 seconds. If the annealing 
temperature >=60ºC, then a shuttle PCR was performed where each cycle has a 5 seconds 
denaturation step at 95ºC followed by a 34 seconds primer annealing step at the specified 
annealing temperature. If the annealing temperature is <60ºC, then after 5 seconds 
denaturation step at 95ºC, a 20 seconds annealing step at the specified annealing temperature 
is performed followed by a 30 seconds extension step at 72ºC.  
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2.4.4 Real-time Methylation Specific PCR 
The real-time PCR system is based on the detection and quantitation of the signal of a 
fluorescent reporter which increases in direct proportion to the amount of PCR product in a 
reaction at each cycle (Lee et al. 1993; Livak et al. 1995). The higher the starting copy 
number of the nucleic acid target, the sooner a significant increase in fluorescence is 
observed. The cycle number at which the fluorescence emission exceeds the fixed threshold 
is defined as CT. Therefore, the more initial target templates present, the smaller the CT value 
is. The difference between the CT of each sample indicates the difference between the initial 
sample size or initial copy number. 
Since partial hypermethylation or partial hypomethylation could not be detected by 
traditional MS-PCR, real-time MS-PCR turns out to be the appropriate way to detect the 
difference between initial amount of unmethylated amplicons and methylated amplicons 
quantitively.  
SYBR green was used as a reporter dye in the real-time PCR. It is a fluorogenic minor 
groove binding dye that exhibits little fluorescence when in solution but emits a strong 
fluorescent signal upon binding to double-stranded DNA (Morrison et al. 1998). The 
disadvantage of this reporter dye is that none-specific PCR products interfere with the target 
signal. But SYBR green is a less expensive reagent which is ideal if there is no non-specific 
PCR product. 
Real-time PCR amplifications were performed by using ABI PRISM

 7000 Real- PCR 
system. 2µl of modified DNA (50-100ng), 0.6µl of primers (final concentration is 75nM), 
10µl of ABSOLUTE™ QPCR SYBR
®
 Green Mixes  (ABgene Inc., USA) and 7.4 µl of 
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water end up 20 µl as total per reaction. All reactions were subjected to the an initial 
denaturation step at 95ºC for 15 minutes. The parameters for the rest of the cycles are same 
as those described in Methylaiton Specific PCR. 
A dissociation curve analyses starting at 60ºC has to be performed after real-time PCR 
amplification steps. Dissociation curve is used to detect the presence of non-specific 
amplification products in SYBR-green real-time PCR. 
Three replicates of each DNA sample were analyzed at the same time. Unmethylation 
and methylation real-time PCR were also carried on the same plate at the same time. The 
average value of CT from each sample was calculated and compared. Table 2.1 lists primer 
names, sequences, product base pair size, annealing temperatures, and sources. 
2.5 Reagents 
The TAKRA polymerase (Premix Ex Taq
TM
) was purchased from Takara Mirus Bio 
which is a newly-formed joint venture between Takara Bio Inc. and Mirus® Corporation. 
ABSOLUTE™ QPCR SYBR
®
 Green Mixes were purchased from ABgene Inc., USA. The 
primers used in the assay were purchased from Integrated DNA Technologies, INC (IDT). 
Primers were diluted upon arrival with 1X TE buffer to 100µM as stock. Primer stocks were 
further diluted to 2.5 µM before use in PCR anaylses. Unmethylated and methylated controls 
were purchased from Serologicals Corporation (United Kingdom). All reagents were stored 
in a standard freezer at -20
o
C and thawed on ice before use. 
2.6 Statistics Analysis 
For MSP, Chi-Square Test was used to determine if the methylation patterns were 
significantly different between the tissue types. For real time PCR, one way ANOVA was 
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performed, and tissue type was considered as fixed effects. This statistical analysis 
determined if different pathological types had significant differences regarding to the 
methylation pattern. A p value which is equal to or less than 0.05 is considered to 
demonstrate a statistically significant difference between pathological types.  
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Table 2.1  Primer sets of all the genes 
Primer Set Forward Primer 
5’ 3’ 
Reverse Primer 
5’ 3’ 
Size 
bp 
Annealing
Temp( 
o
C) 
(1,2)RASSF1A-U TAAATTGGATTAGG
AGGGTTAGGGTT 
CCCAAAATCCAAACT
AAACAACAAA 
290 61 
(1,2)RASSF1A-M ATCGGATTAGGAG
GGTTAGGGTC 
CCAAAATCCAAACTA
AACGACGA 
289 61 
(2)RASSF1A-U GGTAGTTGGTTTTT
GGTTGTGGTTATT 
ACCTAATCCTCAAAA
ACTATCCCCAC 
237 61 
(2)RASSF1A-M TGGTTTTTGGTCGT
GGTTATCGT 
TCCTCGAAAACTATCC
CCGC 
225 61 
(1)DAPK1-U AGTATTTTGGGAGG
TTTAGGTGG 
TCCCCAATAACTAAA
ACTACAATCAC 
145 56 
(1)DAPK1-M TTAGTATTTTGGGA
GGTTTAGGC 
TCCCCAATAACTAAA
ACTACAATCG 
147 56 
(2)DAPK1-U AGTTGTGTTTTTGTT
GTTGTTTTGG 
CCACCTTAACCTTCCC
AATTACTCA 
224 58 
(2)DAPK1-M TTAGTTGTGTTTTC
GTCGTGTTTC 
GCCTTAACCTTCCCAA
TTACTCGA 
224 57 
(4)DAPK1-U GAGATTGATGTATG
AGGGGGTTAT 
TACCAAATTCCTCACC
AATATCATA 
164 55 
(4)DAPK1-M GAGATTGATGTATG
AGGGGGTTAC 
AATTCCTCGCCGATAT
CGTA 
159 55 
(1)BRCA2-U AATTATTTGATTTTT
GGAGGTGG 
ACAAAATTTCACTCTT
ATAACCCAAA 
87 65 
(1)BRCA2-M GAGAATTATTTGAT
TTTTGGAGGC 
GAAATTTCGCTCTTAT
AACCCG 
88 65 
(2)BRCA2-U GTTTTTGAAATTAG
GTGGTAGAGGTGG 
CAAAAACAAAAAAAC
AAAAAACCACAAC 
297 55 
(2)BRCA2-M AGTTTTTGAAATTA
GGCGGTAGAGGC 
AAAAACAAAAAAACA
AAAAACCGCG 
297 55 
(4)BRCA2-U GATATGTTGATGGG
AATTATTAGGTG 
ATACCACTAACCACA
TTAAACACTCAA 
164 61 
(4)BRCA2-M GATATGTTGATGGG
AATTATTAGGC 
ATACCACTAACCACA 
TTAAACACTCG 
164 61 
H19-U GTTTGGGAGAGTTT
GTGAGGTTGT 
TCCAATTAACCAAAC
TTATACTAATCACCA 
187 58 
H19-M GGTTTGGGAGAGTT
TGTGAGGTC 
CCAATTAACCGAACT
TATACTAATCACCG 
187 58 
 
1: The number in the ( ) indicates the location of the CpG island. For example: (1) indicates 
the first CpG island which is located furthest away from the start codon of the gene. 
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CHARPTER THREE 
RESULTS 
 
3.1. Sequence Alignment 
In order to design primers at the CpG islands at promoter regions of each gene, it is 
necessary to find the correct 5’ upstream transcription region (UTR) and partial coding 
region first. Sequences from previous published papers were all based on mRNA sequence 
from genebank. Published primers for RASSF1A (genebank NM_007182) and DAPK1 
(genebank X76104) were initially tried, but the results of MSP were very inconsistent. New 
primers sets were designed for these two genes as noted below. The first set of primers 
designed for BRCA2 were based on the genebank DNA sequence (NM_000059), but failed 
to provide the expected MSP bands. In order to solve this MSP primer design, a new 
approach to designing MSP primer sets was needed. Genome Browser is a new online 
genomic database which launched on 2004 with more complete genomic sequences and 
functions, which could specify the sequence of exon, intron and start codon. UTG and 
partial coding sequence alignment between genebank and Genome Browser were 
performed in order to obtain a more accurate sequence for each gene.  
 Alignment for RASSF1A (Fig 3.1.a) using genebank sequence NM_007182 provided 
the complete sequence of exon1 on chr3:50342221-50353371. Alignment for RASSF1A 
(Fig 3.1.a) showed NM_007182 provided the complete sequence of exon1 on 
chr3:50342221-50353371. Genome Browser shows DAPK has three isomers which are 
DAPK1, DAPK2 and DAPK3. DAPK1 is located at  chr9:87341696-87553100 
(CR749834), DAPK2 is located at chr15:61986288-62125574 (NM_014326), and DAPK3 
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is located at  chr19:3909451-3920826 (NM_001348). Previous published papers 
regarding methylation status of DAPK were based on gene bank X76104. Alignment for 
X76104 showed that these sequences were actually at chr9 which meant it actually refered 
to DAPK1. But alignment for DAPK1 showed that UTG sequence from X76104 was split 
by intronic sequences (Fig3.1.b). Part of the sequence was in the first intron, and the rest of 
the sequence was in the second exon which resides on chr9:87,341,697-87,553,100. 
Alignment for BRCA2 sequences also demonstrated that the UTR sequences from 
NM_000059 are devided on chr13:31787617-31788610. Part of the sequence is on the  
first exon, while the rest is on the second exon (Fig 3.3c). Sequences for H19 were taken 
used from Genome Browser, because there was no specific UTR sequence provided by 
genebank.  
 
 
Figure3.1 a: Alignment of RASSF1A.b: Alignment of DAPK1. C: Alignment of BRCA2. 
Matching bases in coding regions of cDNA from genebank and genomic sequences are 
colored blue and capitalized. Matching bases in UTR regions of cDNA and genomic 
sequences are colored red and capitalized. Grey highlighted sequences are exons. 
(a) 
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(fig.cont’d) 
 
(b) 
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(fig.cont’d) 
 
 
 
3.2. RASSF1A 
Agathanggelou et al (2005) mentioned actually there are two CpG islands are associated 
with the promoter regions of RASSF1. The first and also the smaller of the two spans the 
promoter region of RASSF1A (and RASSF1A, RASSF1E, RASSF1F, and RASSF1G). The 
second CpG island encompasses the promoter regions for RASSF1B and RASSF1C. The 
entire first exon of each RASSF1 transcript is contained within the CpG islands. Using 
MethPrimer, two CpG islands were identified in the estimated promoter region and 
extended regions. The first CpG island was located before the first exon and the second 
(c) 
 28 
CpG island expanded from the end of the promoter region into and through Exon1 and 
partway into Intron1 (Figure 3.2) .The size, start point and end point of each CpG island on 
the input sequence are listed at table 3.1. Since there are only 8 bp apart, these two islands 
could be considered as one which is concordance to the smaller one that Agathanggelou et 
al. mentioned.  
 
Figure 3.2: The distribution of CpG islands at RASSF1A. 
 
Table 3.1. CpG islands of RASSF1A 
 Size(bp) Start - End 
Island 1 133  795 -  927 
Island 2 559 935 - 1493 
 
Two sets of primers were designed to study the methylation status of RASSF1A. The 
first primer sets (both U and M primers) amplified the region across both islands but before 
the start codon. A total of 8 samples were analyzed and were all found only unmehtylated. 
However, the bands were not very clear and the results questionable. 
The second sets of primers designs were positioned right after the start codon of 
RASSF1A but within the second CpG island region. A total of 118 samples were analyzed 
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and the results are listed in table 3.10 and figure 3.3.  
Methylation was found in twenty three of fifty two (44.2%) samples of vulvar SCC and 
eleven of twenty six (42.3%) normal tissues samples (Table 3.2). But there were only seven 
out of forty (17.5%) lichen sclerosis tissues. The methylation of SCC specimens using the 
RASSF1A primer was found to be significantly higher than lichen sclerosis tissues 
(p=0.0067), but not significantly different from normal tissue (p=0.8717). Lichen sclerosis 
was also significantly less methylated than Normal tissue (p=0.0270).  
 
Figure3.3 Representative samples of MSP analysis of the RASSF1A gene on the 2nd CpG 
island 
 
Table 3.2. The methylation status for RASSF1A 
 Unmethylated Methylated Total Methylation (%) 
Normal 15 11 26 42.3 
LS 33 7 40 17.5 
SCC 29 23 52 44.2 
 
3.3. DAPK1 
Four CpG Islands were found in the DAPK1 gene sequence with the Methprimer 
software. The first CpG island is located in the promoter region. The second and the third 
CpG island are both located within the first inron. The fourth CpG island extends from the 
end of Inron1 to almost the end of Exon2 (Figure 3.4). The size, start point and end point of 
each CpG island are listed at table 3.3.  
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Figure3.4: The distribution of CpG islands at Dapk1 
 
Table3.3. The distribution of CpG islands of DAPK1 
 Size(bp) Start - End 
Island 1 224 403 - 626 
Island 2 1119 1322 - 2440 
Island 3 238 2456 - 2693 
Island 4 206 2456 - 2693 
 
Three sets of primers were designed for studying the methylation status of DAPK1 
within the first, second and fourth CpG islands. Eight samples were analyzed for the first 
CpG island region, and twenty samples were analyzed for the fourth CpG island region. All 
of the samples showed both bands for unmethylation and methylation on both regions 
(Figure 3.5).  
A total of 107 samples were analyzed by MSP on the second CpG island (Table 3.10, 
Figure 3.5). From table 3.4, hypermethylation was found in twenty three of fourty four 
(52.3%) samples of vulvar SCC and eighteen of thirty seven (48.7%) lichen sclerosis 
samples. But there were only six out of twenty six (23.0%) normal specimens found to be 
 31 
hypermethylated. The methylation of SCC specimens was found to be significantly higher 
than adjacent normal tissues (p=0.0166), as was lichen sclerosis tissues compared to 
normal tissues (p=0.0396). However, the occurrence of methylation in SCC samples was 
not significantly different from lichen sclerosis samples (p=0.7452).  
 
 
 
 
 
 
Figure 3.5 Representative samples of MSP analysis of the DAPK-1 gene. location: a)1st 
CpG island, b)2nd CpG island, c)4th CpG island 
 
Table 3.4. The methylation status of the second CpG island of DAPK1 
 Unmethylated Methylated Total Methylation (%) 
Normal 20 6 26 23.0 
LS 19 18 37 48.7 
SCC 21 23 44 52.3 
 
3.4. BRCA2 
Four CpG Islands were found in BRCA2 sequence using the Methprimer program 
(Figure 3.6). The first CpG island is located in the promoter region and the second CpG 
island extended from the end of the promoter region into and through Exon1 and partway 
(a) 
(b) 
(c) 
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into Intron1. The third and the fourth CpG islands are both located within Intron 1 (Figure 
3.4). The size, start point and end point of each CpG island are listed at Table 3.5. 
 
 
 
Figure3.6. The distribution of CpG islands at BRCA2 
 
Table3.5. Distribution of CpG islands of BRCA2 
 Size(bp) Start - End 
Island 1 140 259 - 398 
Island 2 496 836 - 1331 
Island 3 127 1349 - 1475 
Island 4 166 1616 - 1781 
 
Three sets of primer sets were designed to study the methylation status of BRCA2 
within the first, second and fourth CpG islands. Seven samples were analyzed for the first 
CpG island region, and twenty three samples were analyzed for the fourth CpG island 
region. All of the samples showed both unmethylation and methylation bands on both the 
first and fourth CpG regions (Table 3.10, Figure 3.7). Fifteen samples for the second CpG 
island region showed only unmethylation (Table 3.10, Figure 3.7). 
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Figure 3.7 Representative samples of MSP analysis of the BRCA2 gene. location: a)1st 
CpG island, b)2nd CpG island, c)4th CpG island 
 
Since regular MSP could not detect changes in the methylation level of Brca2, real-time 
PCR was performed using the fourth CpG island primer set. Three replicates of each sample 
for both U and M PCR were performed.  
Dissociation curves starting at 60 
o
C were performed after 40 cycles to ensure there were 
no non-specific PCR products. A single product would show a single sharp peak at its melting 
temperature, but non-specific products such as primer dimers would show another sharp peak 
at its own melting temperature (Figure 3.8). Dissociation curves depend on PCR products’ 
GC content, size etc. Therefore, even two products with same size but different GC content 
could be differentiated by dissociation cures which could not be seperated by regular 
electrophoresis. The determination of dissociation curves is a necessary and powerful step 
which should be included in SYBR-green real-time PCR. 
(b) 
(c) 
(a) 
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Figure 3.8. Dissociation curve for one replicate of sample 35-3 and blank 
 
Twenty five samples were analyzed by real-time PCR using the same primer sets as 
regular MS-PCR (Table 2.1).Only fifteen samples gave valid data due to the presence of 
non-specific products (Table 3.9). Primer dimers tended to form when the initial 
concentrations of DNA templates were low. For example, sample CW 70-5 (Figure 3.9), all 
three replicates of the U reaction showed products and dimers, while only pure M Products 
were observed in the same sample. This phenomena could be because there were not enough 
unmethylated templates in the sample due to hypermethylation. Other samples had dimers in 
both U and M reactions, which might because there were not enough templates left after 
bisulfite treatment.  
As mentioned in Methods, Ct value is the cycle number when the fluorescence light 
produce by SYBR-green attached to products reached the threshold. The greater the initial 
number of templates, the earlier the product fluorescence light would reach to the threshold. 
The difference of the Ct value (Dct) between U and M PCR reactions from each sample would 
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indicate if the methylation level of the original copy number increases or decreases (Figure 
3.10). 
 
Figure 3.9 Dissociation curve for one replicate of sample 70-5  
 
 
Figure 3.10 Applification plot of sample CW 35-3.The Green line is the threshold, and the 
cycle number that the Delta Rn reaches the threshold is the Ct Value for that reaction. 
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Since the amount of fluorescence light is proportional to the total amount of the product, 
and the PCR product size of U and M are same. Therefore, if we assume the reaction 
efficiencies for both sets of primers are same, we can give an estimation of the proportion of 
the initial unmethylated templates and methylated templates in a heterozygous cell. Using Ui 
to represent the percentage of initial amount of unmethylated templates, Mi to represent the 
percentage of initial amount of methylated templates, a and b represent the Ct value for U 
reaction and M reaction respectively. By the time both reaction reached to threshold, the total 
templates in each reaction should follow equation below: 
b
i
a
i
MU 2*2* =     (Equation 3.1) 
  100=+ ii MU     (Equation 3.2) 
Therefore, we can find that the proportion of methylated templates is : 
( ) 12
100
+
=
− abi
M     (Equation 3.3) 
Based on equation 3.3, we can estimate how much percentage of methylated templates and 
whether it increases or decreases in each sample.  
Three replicates of each sample were performed, but not every replicate gave a specific 
product. Only data from those replicates that showed no non-specific products were used. 
However, it was necessary to use at least two replicates for each sample to ensure accuracy. 
Therefore, only fifteen samples had at least two replicates with pure products. Also, due to 
experiment error, even those samples with all three replicates having specific products did not 
have similar Ct values. Sometimes one of the Ct values would be different from the other two 
replicates’ values. In this situation, only the two Ct values close to each other were chosen. 
Means of Ct values, Dct values and M values of all the replicates for each sample and each 
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type of reaction were calculated for final analysis (Table 3.6)  
Table 3.6.The average values of each sample  
Sample tissue 
type 
Average 
Ct (M) 
Average 
Ct (U) 
Average 
Dct 
Average 
% of U 
Average 
% of M 
14-7 N 26.0933 24.4700 1.6233 75.4954 24.5046 
2b N 23.9933 22.4033 1.59 75.0658 24.9342 
30-2 N 25.1767 22.8633 2.3133 83.2507 16.7493 
39-1 N 24.3733 22.2900 2.0833 80.9082 19.0918 
40-4 N 26.0700 23.0867 2.9833 88.774 11.226 
41-2 N 25.3467 22.735 2.6117 85.9394 14.0606 
52-2 N 31.4350 30.0250 1.41 72.658 27.342 
52-1 LS 25.1033 24.06 1.0433 67.3308 32.6692 
52-6 LS 25.2400 23.8800 1.36 71.9641 28.0359 
27-1 SCC 24.2400 22.9033 1.3367 71.6371 28.3629 
35-3 SCC 28.3867 26.7633 1.6233 75.4958 24.5042 
50-4 SCC 32.0833 30.6300 1.4533 73.2506 26.7494 
50-7 SCC 30.9300 29.1400 1.79 77.5692 22.4308 
63-1 SCC 28.7700 27.2100 1.56 74.6742 25.3258 
91-2 SCC 26.5167 25.2550 1.2617 70.5685 29.4315 
 
Least Square Means were calculated for the percentage of mehylation templates (M) and 
the differences of the Ct values (Dct) were based on the tissue type (Table 3.7). ANOVA 
analysis performed for both M and Dct based on the tissue type, and comparison between 
each type of tissue were also performed (Table3.8, table 3.9) 
 
Table 3.7 Estimated Least Squares Means of Dct and M 
Tissuetype 
Estimated 
Dct 
Standard 
Error (Dct) 
Estimated 
M 
Standard 
Error (M) 
N 2.0879      0.1651 19.7012 1.7780 
LS 1.2017       0.3088 30.3526 3.3263 
SCC 1.5042      0.1783 26.1341 1.9205 
 
Table 3.8 Differences of Least Squares Means of Dct 
Effect 
Tissuetype- 
Tissuetype 
Estimate 
Standard 
Error 
Df t Value Pr>|t| 
tissuetype LS_N -0.8862 0.3502 12 -2.53 0.0264 
tissuetype LS_SCC -0.3025 0.3566 12 -0.85 0.4129 
tissuetype N_SCC 0.5837 0.243 12 2.4 0.0334 
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Table 3.9 Differences of Least Squares Means of percentage of methylation 
Effect 
Tissuetype- 
Tissuetype 
Estimate 
Standard 
Error 
Df t Value Pr>|t| 
tissuetype LS_N 10.6513 3.7717 12 2.82 0.0153 
tissuetype LS_SCC 4.2185 3.8409 12 1.1 0.2936 
tissuetype N_SCC -6.4329 2.6171 12 -2.46 0.0301 
The results demonstrates that the value of Dct and percentage of methylated templates (M) 
varied based on tissue type. The mean Dct value of normal tissues was significantly higher 
than that of lichen sclerosis (LS) tissue (p=0.0264), and that of SCC (p=0.0334), but the mean 
Dct values between SCC and LS were not significantly different (p=0.4129). The percentage 
of methylated templates of normal tissue was significantly less than that of LS (p=0.0153), 
and less than that of SCC (p=0.0301), but SCC and LS were not significantly different 
(p=0.2936). 
Real-time PCR was also performed at the first CpG island by using the same primers 
for MSP listed at table 2.1, but no accurate results were collected since dissociation cures 
indicated non-specific products constantly existed at the methylation PCR reaction no 
matter what conditions were used. Gel electrophoresis also verified that primer dimmers 
were the consistent non-specific products which interfered the results.  
3.5 H19 
 H19 is located on chr11:1,972,984-1,975,280. Only one CpG island was found in the 
gene sequence using the Methprimer program. The size, start point and end point of the 
CpG island at input sequence are listed at table 3.8, shown in figure 3.11. 
 H19 is a maternal imprinted gene. Seven samples were tested with MSP and both U and 
M bands were displayed in all cases. Therefore, real-time PCR was tested for the detection 
of a change in each sample. Three different sets of primers were designed and tested in 
 39 
real-time PCR (Figure3.12). Unfortunately, dissociation curves showed there were 
consistant primer dimmers in the products from every set of primers. Therefore, real-time 
PCR with SYBR-green as reporter dye failed to detect changes in the methylation level for 
H19.   
 
 
 
Figure3.11. The distribution of CpG islands at H19 
  
 
   Table 3.8. CpG islands of H19 
 Size(bp) Start - End 
Island 1 133  795 -  927 
 
 
Figure 3.12 Representative samples of MSP analysis of the H19 gene from one primer 
sets. 
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Table 3.9 Real-time PCR data of BRCA2 
Sample PCR type TissueType Ct Value 
35-3  U SCC 27 
35-3  U SCC 26.66 
35-3  U SCC 26.63 
35-3  M SCC 28.36 
35-3  M SCC 28.44 
35-3  M SCC 28.36 
52-1  U LS 24.07 
52-1  U LS 24.04 
52-1 U LS 24.07 
52-1  M LS 25.11 
52-1  M LS 25.02 
52-1  M LS 25.18 
14-7 U N 24.5 
14-7  U N 24.44 
14-7  M N 26.17 
14-7  M N 26.02 
14-7  M N 26.09 
52-6  U LS 23.78 
52-6  U LS 23.87 
52-6  U LS 23.99 
52-6  M LS 25.14 
52-6  M LS 25.27 
52-6  M LS 25.31 
91-2  U SCC 25.14 
91-2  U SCC 25.37 
91-2  M SCC 26.43 
91-2  M SCC 26.48 
91-2  M SCC 26.64 
2b  U N 22.51 
2b  U N 22.25 
2b  U N 22.45 
2b  M N 23.97 
2b  M N 23.9 
2b    M N 24.11 
30-2  U N 22.93 
30-2  U N 22.88 
30-2  U N 22.78 
30-2  M N 25.16 
30-2  M N 25.13 
30-2  M N 25.24 
41-2  U N 22.43 
41-2  U N 23.04 
41-2  M N 25.44 
41-2  M N 25.38 
41-2  M N 25.22 
(TABLE continued) 
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27-1  U SCC 22.9 
27-1  U SCC 22.85 
27-1  U SCC 22.96 
27-1  M SCC 24.31 
27-1  M SCC 24.2 
27-1  M SCC 24.21 
50-4 U SCC 30.98 
50-4 U SCC 30.28 
50-4  M SCC 31.48 
50-4  M SCC 32.69 
50-4  M SCC 32.08 
50-7 U SCC 29.14 
50-7  U SCC 29.14 
50-7  M SCC 30.78 
50-7  M SCC 31.08 
63-1  U SCC 26.89 
63-1  U SCC 27.44 
63-1 U SCC 27.3 
63-1  M SCC 29.1 
63-1  M SCC 28.64 
63-1  M SCC 28.57 
39-1 U N 21.93 
39-1 U N 22.65 
39-1 M N 24.41 
39-1 M N 24.19 
39-1 M N 24.52 
40-4 U N 22.77 
40-4 U N 23.25 
40-4 U N 23.24 
40-4 M N 26.02 
40-4 M N 26.1 
40-4 M N 26.09 
52-2 U N 29.81 
52-2 U N 30.24 
52-2 M N 31.51 
52-2 M N 31.36 
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Table 3.10 MSP analysis of each sample 
RASSF1A DAPK1 BRCA2 H19 
Sample Type 
1st 
CpG 
2nd 
CpG 
1st 
CpG 
2nd 
CpG 
4th 
CpG 
1st 
CpG 
2nd 
CpG 
4th 
CpG 
1st 
CpG 
CW 5-4 LS          +         
CW 5-5 LS                   
CW 7-1 SCC                   
CW 10-1 SCC                   
CW 11-1 SCC                   
CW 12-1 SCC                   
CW 12-2 SCC                   
CW 12-4 SCC                   
CW 13-2 N                   
CW 13-4 N                   
CW 14-1 SCC                   
CW 14-2 SCC                  
CW 14-7 N                   
CW 16-2 SCC                   
CW 16-3 N                   
CW 17-1 SCC                   
CW 17-5 N                   
CW 17-6 LS                   
CW 18-1 SCC                  
CW 18-2 SCC                   
CW 18-5 N                   
CW 18-6 SCC                   
CW21-1 SCC                   
CW 21-3  LS                   
CW 22-1 SCC                  
CW 22-2 LS                   
CW 22-3 LS                  
CW 22-4 LS                   
CW 23-1 SCC                 
CW 23-3 N                  
CW 24-1 SCC                   
CW 25-1 SCC                  
CW 25-2 N                  
CW 26-2 SCC                   
CW 27-1 SCC                  
CW 28-1 SCC                   
CW 28-3 LS                   
CW 28-5 LS                   
CW 28-B N                  
CW 29-1 SCC                  
CW 29-3 N                   
CW 29-4 LS                   
(TABLE continued) 
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CW 29-5 LS                  
CW 29-6 SCC                  
CW 29-B N                   
CW 30-1 SCC                   
CW 30-2 N                   
CW 30-3 LS                   
CW 30-5 LS                  
CW 31-2 LS                   
CW 31-3 LS                  
CW 35-2  LS                   
CW 35-3 SCC                   
CW 35-5 LS                   
CW 35-6 LS                   
CW 39-1 N                  
CW 39-3 N                  
CW 40-1 SCC                   
CW 40-2 SCC                  
CW 40-4 N                   
CW 41-1 SCC                   
CW 41-2 N                  
CW 43-1 SCC                   
CW 43-3 SCC                   
CW 43-4 SCC                  
CW 44-1 N                   
CW 44-2 SCC                  
CW 44-3 LS                  
CW 44-4 LS                  
CW 44-5 LS                  
CW 44-7 LS                   
CW 45-4 N                  
CW 45-5 LS                   
CW 46-3 LS                   
CW 46-4 LS                   
CW 46-5 LS                  
CW 46-6 LS                   
CW 46-7 LS                  
CW 47-2 SCC                   
CW 47-3 LS                  
CW 47-4 LS                  
CW 49-1 SCC                  
CW 49-3 SCC                  
CW 49-4 LS                   
CW 49-5 LS                  
CW 49-6 LS                   
CW 50-1 SCC                   
CW 50-2 SCC                  
CW50-4 SCC                  
(TABLE continued) 
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CW 50-5 LS                   
CW 50-6 SCC                  
CW 50-7 SCC                   
CW 52-1 LS                   
CW 52-2 N                   
CW 52-6 LS                   
CW 53-1 LS                   
CW 53-2 LS                  
CW 53-3 LS                   
CW 57-1 SCC                  
CW 57-3 N                   
CW 60-1 N                   
CW 60-3 N                   
CW 61-1 SCC                   
CW 61-2 LS                  
CW 61-4 LS                  
CW 61-6 SCC                   
CW 62-1 N                 
CW 63-1 SCC                  
CW 63-2 SCC                 
CW 63-5 SCC                 
CW 64-3 SCC                  
CW 66-3 LS                  
CW 66-4 LS                  
CW 70-1 LS                  
CW 70-2 SCC                   
CW 70-3 SCC                   
CW 70-4 LS                   
CW 70-5 LS                   
CW 70-6 LS                   
CW 73-1 N                   
CW 89-1 SCC                  
CW 89-2 SCC                   
CW 91-1 SCC                   
CW 91-2 SCC                   
CW 93-1 SCC                  
CW 93-2 SCC                   
CW 97-1 SCC                  
CW 98-1 SCC                  
CW 98-4 SCC                   
CW 106-3 N                   
CW 108-1 N                   
Black cell: Sample both methylated and unmethylated 
Grey cell: Sample only unmethylated 
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CHAPTER FOUR 
DISSCUSSION 
 
4.1 General Discussion 
The promoter regions of four genes have been studied for the methylation pattern in 
normal vulva tissue to Lichen Sclerosis and Squamous Cell Carcinoma. Since the study 
region for RASSF1A was designed after the transcription start codon, an interesting 
methylation pattern was observed that was different from the majority of published results 
(Burbee et al. 2001; Kim et al. 2003; Kuroki et al. 2003; Wang et al. 2004). The frequency 
of methylation in RASSF1A significantly decreased (p=0.0270 ) from normal to LS, then 
dramatically increase (p=0.0067) from LS to SCC. DAPK-1 was found to be significantly 
hypermethylated in LS and SCC tissues, which is similar to previous studies on other 
cancers (Katzenellenbogen et al. 1999; Lehmann et al. 2002; Tada et al. 2002). BRCA2 was 
found to be hypermentylated in one of its CpG islands in both LS and SCC tissues. In the 
analysis of the H19 gene, an imprinted gene, real-time PCR failed to detect changes in 
methylation in diseased specimens. These results demonstrated that different methylation 
patterns of RASSF1A, DAPK-1 and BRCA2 genes were detected based on different vulva 
specimen disease states, and indicate that epigenetic events might be involved in or 
associated with preneoplastic and early tumorigenesis.  
4.2 RASSF1A 
Although more than 90% of published papers listed on Pubmed have reported that 
RASSF1A promoter hypermethyltion was associated with reduced mRNA expression in 
tumors, the present studies display quite different results from previous studies. The 
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frequency of hypermethylation of RASSF1A was found to be the same in vulva SCC and 
normal tissue (44.2% and 42.3%, respectively). However, vulvar Lichen sclerosis (LS) 
tissue only showed 17.5% methylation frequency. Methylation frequency significantly 
decreased (p=0.027) from normal tissue to LS, and significantly increased (p=0.0067) 
from LS to SCC. But there is no statistic significance between the Normal and SCC. 
As shown in Figure 3.2, the CpG island studied spans the 5’UTG region through first 
exon and extends past the transcription start codon. Since previous reports focused on only 
the 5’UTG region, the present results help clarify progressive changes in methylation of 
developing skin SCC. The majority of published reports used primers  located within the 
CpG island located before the transcription start site. Primers for MSP which amplify the 
region starting from the end the 5’ UTR and passing first exon but before the transcription 
start codon were published by Burbee et al. (2001), and have been frequently used by other 
papers. For examples,  Kuroki et al. (2003) found hypermethylation in esophageal 
squamous cell carcinoma sample (52%) vs. only 4% in noncancerous tissues; Kim et al. 
(2003) reported hypermethylation occurred 26% of lung squamous cell carcinoma and 
Wang et al. (2004) reported hypermethylation was detected in 39% non-small cell lung 
cancer tissue and only 3% in corresponding normal appearing lung tissues. 
 Methylation analyses of the CpG island located after the transcription start site of 
RASSF1A has however also been reported. Spugnardi et al. (2003) assessed two different 
regions of the RASSF1A CpG island located on both sides of transcription start codon to 
study aberrant methylation. Region 1 was located upstream of the transcription start codon 
and contained three Sp1 consensus binding sites, and the primers for the MSP were similar 
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to those reported by Burbee et al. (2001). Region 2 was located within the first exon 
immediately after the transcription start codon which is specific to the RASSF1A transcript 
and similar to the current studied region. Hypermethylation of RASSF1A region 1 was 
found in 41% of melanoma tumors, of which 33% of stage III melanoma patients, and 44% 
of stage IV patients. Analysis of RASSF1A region 2 revealed aberrant methylation in 50% 
of melanoma tumors with only 22% of stage III patients, but 56% of stage IV patients. 
There was an increasing frequency of methylation through the tumor passage on region 2, 
which is similar to my results showing the methylation frequency increase dramatically 
from LS to SCC (17.5% to 42.3%). No methylation was detected in available normal skin 
tissues or healthy donor peripheral lymphocytes, but Spugnardi et al. (2003) did not clarify 
whether the normal tissues were normal adjacent tissue or normal non-adjacent tissue. 64% 
and 82% of melanoma cell lines have been reported to be methylated in region1and region 
2, respectively (Spugnardi et al. 2003). Hypermethylation was higher in RASSF1A region 2 
in both cell lines and tumors, and RT-PCR revealed that samples where both regions were 
methylated lacked RASSF1A gene expression (Spugnardi et al. 2003). Although at present, 
the mechanisms of de novo methylation of tumor suppressor genes and other regulatory 
genes are poorly understood, Spugnardi et al.  proposed that it is possible that the 
hypermethylation event initiated in region 2 (exon 1) and then spread into region 1, the 
upstream promoter region, which ultimately results in gene silencing.  
Strunnikova et al. (2005) also investigated the methylation pattern of Human 
mammary epithelial cells (HMEC) in different regions of the RASSF1A gene including a 
region similar to that reported by Spugnardi et al. (2003) which contained three Sp1 
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binding sites and the transcription start site (RA region), an upstream region to RA (U1) 
and a downstream regions (D1). All of these regions were unmethylated in normal human 
fibroblasts, blood leukocytes, and Hela cells. The RA region was completely unmethylated 
in prestasis and stasis HMEC, and only methylated in postasis cells. Stasis is the state, in 
which the normal flow of a body liquid stops, for example the flow of blood through 
vessels or of intestinal contents through the digestive tract (Wikipedia contributors 2005). 
However, both U1 and D1 which flanked the transcription initiation site exhibited frequent 
methylation along with further increase in methylation in later passages of HMEC cultures. 
RASSF1A was also dramatically silenced with increasing passages. My work has shown 
that methylation dramatically increased from LS to SCC. My work also found that normal 
tissues were also highly methylated. Unfortunatley, Strunnikova et al. (2005) did not report 
the methylation pattern in the normal tissues. Based on the published results, Strunnikova 
et al. (2005) also proposed there might be a spreading of de novo DNA methylation from 
the methylated upstream and downstream regions into the RASSF1A CpG island promoter. 
It appears that the primary control of gene expression may be due to methylation 
status of the CpG island in the RASSF1A promoter region. However, understanding the 
progressive changes in RASSF1A gene methylation in cancer development may require the 
analysis of CpG islands before and after the start codon. The region that right before the 
start codon which contains three Sp1 sites is frequently hypermethylated in human tumors 
but unmethylated in normal tissues, while the down stream region is more frequently 
unmethylated in normal tissue and the methylation increases with tumor development. 
Current studies show that the methylation frequency significantly increases from LS to 
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SCC at the down stream region, which is in concordance with previous studies, but it is 
hard to explain that even normal tissues were as frequently methylated as SCC. And it is 
also questionable that the de novo methylation spreading hypothesis proposed by 
Spugnardi et al. and Strunnikova et al is valid.  
4.3 DAPK-1 
At the first and fourth CpG islands in the 5’ region of the DAPK-1 gene sequences, 
MSP results showed both unmethylated and methylated bands were consistantly present in 
all samples analyzed. This indicated that both alleles at these two regions might be 
heterozygous by methylation. However, the second CpG island showed variation of 
methylation patterns in different samples. Relating this information with Figure 3.3, it is 
quite obvious that 5’ upstream region, and the regions slightly before exon2 might not be 
involved in epigenetic events associated with gene expression process, while the first intron 
is probably involved.  
Hypermethylation of CpG islands in DAPK-1 has been frequently observed in various 
types of human malignancies. The methylation results observed for DAPK-1 in the present 
study were consistant with those seen in other studies. This study demonstrated DAPK-1 
was found to exhibit a high frequency of promoter methylation in vulvar Lichen sclerosis 
(LS) and SCC. These values for SCC and LS tissues were both found to be statistically 
different from normal tissues. This relationship showing increasing methylation from 
normal to LS and SCC suggests that epigenetic silencing of DAPK-1 is an early event in 
vulvar neoplasia. These data correlate well with data from others studying SCC and other 
cancers such as 53% in lobular invasive breast cancer, 9% in ductal invasive breast cancer, 
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76.1% in nasopharyngeal carcinoma (NPC), 34%-35% in lung SCC, 29% in epithelium 
bladder carcinoma and 84% in B-cell non-Hodgkin’s lymphomas, (Katzenellenbogen et al. 
1999; Chan et al. 2002; Lehmann et al. 2002; Tada et al. 2002; Mittag et al. 2005) 
4.4 BRCA2  
Few papers about the study of aberrant methylation of the BRCA2 gene have been 
published. Hilton et al. (2002) has reported that only 1 out of 12 (8%) tumors in ovarian 
cancers lacked detectable
 
BRCA2 mRNA showed hypermethylation, but all eight of
 
the 
tumors without detectable BRCA1 mRNA demonstrated BRCA1
 
promoter CpG island 
hypermethylation. Dhillon et al. (2004) also reported a similar low occurrence of BRCA2 
methylation in human primary tumors with only 1 out of 25 (4%) Granulosa cell tumor cell 
lines hypermethylated. Both of these papers used the same primer sets for MSP, which 
were located on the second CpG island as shown on in Figure 3.4, but neither of them 
reported the methylation pattern in the normal tissues. These two papers also hypothesized 
that the methylation pattern might not contribute to gene expression mechanism, although 
other epigenetic events might be involved. It is possible that the region they studied might 
not be involved in epigenetic instability, which also means it might not be the active 
promoter region of BRCA2. 
The second CpG island in the BRCA2 gene sequence extends from 5’ UTR, across the 
exon1 and all the way down to intron1. Since the third island is only 18bp apart from the 
second one, it was grouped together with the second CpG island. Only unmethylated MSP 
patterns were observed at this region, suggesting that both alleles might be homozygous 
unmethylated at this locus.  
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The first CpG island is located in the 5’ UTR, while the fourth CpG island is in the first 
intron but close to the transcription start codon. Both unmethylated and methylated patterns 
were shown by MSP at the these two islands 100% of the time in vulva specimens. However, 
partial variation of the methylation pattern could not be detected by regular MSP at these two 
CpG islands. Real-time PCR revealed that the percentage of copy numbers of methylated 
alleles statistically significantly increased from normal tissue (19.7%) to LS (30.4%) and 
SCC (26.1%), but not between LS and SCC. If we assume both U and M primer sets have the 
same reaction efficiencies, then the results would indicate that there exists an increase of 
methylation of BRCA2 in the LS and SCC tissue specimens compared to adjacent normal 
vulva tissue.  
Another assumption is that the primer sets’ efficiency causes the difference of Ct value’s 
which biased the data increasing the determined methylated templates in the cancer tissues. 
However, from the results, approximately 80.3% of the alleles were unmethylated in the 
normal tissue, but only 19.7% were methylated. It is less likely that this 60.3% difference can 
be explained by the difference between primer sets’ efficiency.  
Overall, from current studies, it appears that the fourth CpG island of BRCA2 is 
frequently methylated in cancer tissue. Although inactivation of BRCA2 through promoter 
hypermethylation
 
has not been reported so far and gene expression level of BRCA2 has not 
been tested in these vulva samples in the current studies, the change of hypermethylation 
patterns still could be a molecular maker for the early stage occurrence of neoplaisa. 
There is only one paper reporting the loss of methylation in BRCA2. Chan et al. (2002) 
has reported a significant correlation between hypomethylation and overexpression of 
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BRCA2. Using enzyme-digested bisufite PCR inclusive of  31 CpG dinucleotides within 
the promoter and 5’-UTR regions, hypomethylation of BRCA2 was observed in 16 out of 
23 cases of sporadic ovarian cancer than in nontumor samples. Unfortunately, the exact 
location of these CpG sites was not reported. Therefore, it is hard to locate the CpG sites in 
the promoter region and compare their results with mine.  
The current real-time PCR approach to these studies was unable to distinguish any 
differences in methylation patterns on the first CpG island. But it is still important to find 
out if any changes in methylation in the first CpG island correlate with changes at the 
fourth CpG island. Gene expression analysis also needs to be done in order to clarify the 
correlation between gene expression and methylation pattern in BRCA2. 
4.5 H19 
H19 is a maternally imprinted gene, and MSP results showed both unmethylation and 
methylation bands for all the specimens studied, further supporting the heterozygosity of 
the two alleles in this imprinted gene. Real-time PCR also failed to differentiate changes in 
the methylation status of H19 in these studies. H19 might be a good indicator sequence if 
variation in methylation patterns could be detected. 
4.6 Real-time PCR 
SYBR-green is a less expensive reagent and more easily used for real time PCR than 
other approaches such as TaqMan and probes. But since it also reports the non-specific 
products along with the amount of final products, the requirements for the primers’ 
efficiency are very high. Low amounts of template could also cause false negative results 
which make it is hard to detect the copy number of unmethylated or methylated templates 
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when hyper- or hypo-methylation has occurred.  
TaqMan is another type of fluorescent reporter method commonly used in Real- time 
PCR. With a matched probe, TaqMan only reports the specific amplicon even in the 
presence of non-specific products. Based on my experience, it may be necessary to use 
TaqMan for future studies in order to detect differences between the template copy 
numbers of unmethylated and methylated templates in target genes. 
4.7 Conclusion and Future Research 
Although aberrant promoter hypermethylation and hypomethylation phenomenon in 
tumor suppressor genes and oncogenes have been well published, the exact promoter 
region and mechanism involved in the change of methylation pattern still remain unclear 
for genes such as RASSF1A. Current studies investigated the CpG islands on a broader 
region, and found there were different methylation patterns on different CpG islands even 
in the same gene. Also since detecting aberrant methylation could be a diagnostic indicator 
of cancer or a molecular marker for the early detection of cancer, it is important to know 
the precise promoter region of each gene.  
Promoter hypermethylation has been found in DAPK-1 and BRCA2 in current studies. 
And an interesting methylation pattern after the transcription codon of RASS1A has also 
been detected. No hypomethylation was detected in any gene in current studies. This 
information will add to the literature regarding the relationship between aberrant 
methylation patterns and early cancer prognosis, and may have potential clinical benefits in 
cancer diagnosis, prevention and treatment. 
Gene expression analysis needs to be performed in order to detect if there is any 
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correlation between the methylation pattern found in current studies and gene expression 
which can further support the involvement of epigenetic events in the transcription process. 
RT-PCR, western blot analysis and chromatin immunoprecipitation (CHIP) could be used 
to detect any change of gene expression, and the sequence associated with the transcription 
factors involved in such epigenetic events.  
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APPENDIX A 
 
PHENOL AND CHLOROFORM EXTRACTION 
PROCEDURE 
 
 
Preparation of Genomic DNA from Mammalian Tissue 
1. Excise an immediately mince tissue quickly and freeze in liquid nitrogen. 
2. Grind 200 mg to 1g tissues with prechilled mortar and pestle, or crush with hammer to fine 
powder. 
3. Add 500 µl grinding buffer to the tissue in a 1.5 ml Eppendorf tube and vortex for 
 several minutes. 
4. Spin the samples in a microfuge for 15 minutes. 
5. Decant the solution and add 500 µl of lysis buffer and add 10 µl (6 Units) of proteinase K 
to each sample. Digest at 37° for 12 hours. 
6. Add 500 µl of phenol to each tube. Vortex briefly and centrifuge for 10 minutes. 
7. Making certain not to disturb the interphase, transfer aqueous top solution to a clean 
labeled tube and add 500 µl of chloroform. Vortex briefly and centrifuge for 10 minutes. 
8. If a white precipitate is present at the aqueous/organic interface, reextract the 
organic phase and pool aqueous phases. 
9. Carefully remove the top aqueous phase containing the DNA using a 200 ulpipettor 
 and transfer to a new tube. 
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APPENDIX B 
ETHANOL PRECIPITATION OF DNA 
 
1. Add 1/10 volume of 3M sodium acetate, pH 5.2, to the solution of DNA. Mix by 
vortexing briefly or by flicking the tube several times with your finger. 
2. Add 2 to 2.5 volumes of ice cold 100% ethanol. Mix by vortexing and place in crushed dry 
ice for 5 minutes or longer. Alternately, the tubes can be placed at -80° for 1 hour or at 
-20° overnight. 
3. Spin 5 minutes in a microcentrifuge at high speed and remove the supernatant. 
4. Add 1 ml of room temperature 70% ethanol. Invert the tube several times and 
microcentrifuge as in step 6. 
5. Remove the supernatant. Dry the pellet in a desiccator under vacuum or in a hood. 
6. Dissolve the dry pellet in an appropriate volume of water or TE buffer (10mM Tris-HCL, 
1mM EDTA), pH8.0 
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APPENDIX C 
BISULFITE TREATMENT OF DNA 
This protocol was adapted from Frommer et.al.1992. 
1. Dilute DNA (up to 2 mg) into 50 ml with distilled H2O. 
2. Add 5.5 ml of 2M NaOH. 
3. Incubate at 37°C for 10 minutes (to create single stranded DNA). 
4. Add 30 ml of 10 mM hydroquinone (Sigma) to each tube, freshly prepared by 
  adding 55 mg of hydroquinone to 50 ml of water. 
5. Add 520 ml freshly prepared 3M Sodium bisulfite (Sigma S-8890), prepared by 
  adding 1.88 gm of sodium bisulfite per 5 ml of H2O, and adjusting pH to 5.0 with 
  NaOH. 
6. Assure that reagents are mixed with DNA. 
7. Layer with mineral oil. 
8. Incubate at 50°C for 16 hours (avoid incubations of much longer duration as 
 methylated C will start converting to T). 
9. Remove oil. 
10. Add 1 ml of DNA wizard cleanup (Promega A7280) to each tube and add mixture 
 to miniprep column in kit. 
11. Apply vacuum (manifold makes this convenient). 
12. Wash with 2 ml of 80% isopropanol. 
13. Place column in clean, labeled 1.5 ml tube. 
14. Add 50 ml of heated water (60-70°C). 
15. Spin tube/column in microfuge for 1 minute. 
16. Add 5.5 ml of 3 M NaOH to each tube, and incubate at room temperature for 5 minutes. 
17. Add 1 ml glycogen as carrier (we use Boehringer glycogen, undiluted). 
18. Add 33 ml of 10 M NH4Ac, and 3 volumes of ethanol. 
19. Precipitate DNA as normal (overnight at -20°C, spin 30 mins), wash with 70% ethanol, 
dry pellet and resuspend in 20 ml water. 
20. Treat DNA like RNA (keep cold, minimize freeze/thaws, store at -20°C)  
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